Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
about
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-SensitivIntegrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations.Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis.
P2860
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Translational predictive bioma ...... izumab study expansion cohort.
@en
type
label
Translational predictive bioma ...... izumab study expansion cohort.
@en
prefLabel
Translational predictive bioma ...... izumab study expansion cohort.
@en
P2093
P2860
P356
P1476
Translational predictive bioma ...... cizumab study expansion cohort
@en
P2093
Aradhana Venkatesan
Ben Davidson
Christina M Annunziata
Clara C Chen
Daniel C Edelman
Elise C Kohn
Lori Minasian
Nilofer Azad
Paul Meltzer
P2860
P304
P356
10.1074/MCP.M112.026427
P577
2013-02-28T00:00:00Z